SARS-CoV-2-IN-119 

SARS-CoV-2-IN-119 (Compound A28) is a SARS-CoV-2 fusion inhibitor. SARS-CoV-2-IN-119 strongly inhibits Omicron entry with an EC₅₀s of 1.95  and 1.08 μM for pOmicron (BA.2.86.1) and wild Omicron. SARS-CoV-2-IN-119 also has antiviral activities against wild SARS-CoV-2 and other variants, such as pseudotyped Delta SARS-CoV-2, pOmicron (BA.4) and (KP.3). SARS-CoV-2-IN-119 directly interferes with Omicron S2-mediated viral membrane fusion to block Omicron virus into host cells. SARS-CoV-2-IN-119 can be used for COVID-19 research^[1].

985.25

C₅₇H₈₀N₂O₁₂

O=C([C@@H]1N(C(C2=C[C@H](O)[C@H](O)[C@@H](O)C2)=O)C[C@@H](OC(C3=C[C@@H](O)[C@H](O)[C@H](O)C3)=O)C1)O[C@H]4CC[C@]5(C)C6CC=C7C8CC(C)(C)CC[C@]8(C(NCCC9=CC=CC=C9)=O)CC[C@@]7(C)[C@]6(C)CCC5C4(C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hong C, et al. Discovery and optimization of OA amide derivatives containing a trisubstituted l-hydroxyproline fragment as novel Omicron fusion inhibitors. Eur J Med Chem. 2025 Dec 5;299:118058.  [Content Brief]